FOLH1 and cancer: Consequently, compared to the beta emitter, TAT results in a more cytotoxic dose to cancer cells while keeping the dose to the surrounding healthy cells minimal.59,100 Kratochwil reported the first human studies of 225Ac-PSMA-617 in two patients who showed positive PSMA expression with PET/CT imaging of 68Ga-PSMA-11.101 After 225Ac-PSMA-617 therapy, the patients showed significantly lower PSA levels and complete imaging responses.